PRNewsWire
01 Jan 2026, 15:00 UTC · 38w ago
Verdict
Headline takes no side. We score ADCT −0.80 across three claims — strongly bearish.
−0.80strongly bearish
More negative than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud or unlawful business practices.
More negative than 95% of claims this week
The LOTIS-7 Phase 1b trial for ZYNLONTA® in combination with glofitamab reported cytokine release syndrome in 36.7% of patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 85% of claims this week
ADC Therapeutics' stock price fell 14.13% to $3.95 following the release of updated LOTIS-7 trial data on December 3, 2025.
More negative than 68% of claims this week
Which stocks this story touches
More negative than 83% of ticker scores this week
The company is being investigated for potential securities fraud following a significant stock price drop and reports of adverse clinical trial events.
More negative than 78% of ticker scores this week
The company is the subject of a class action lawsuit.
More negative than 78% of ticker scores this week
The company is the subject of a class action lawsuit involving investor losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2h ago
−64.3%
Price agrees with the score
$1.26 vs $3.53 close before publication (Dec 31) · not market-adjusted
ADCT chart →
